Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. reports developments for its clinical-stage biotechnology program in fibro-inflammatory diseases. Recurring updates center on nebokitug, an antibody targeting CCL24, and its clinical evaluation in primary sclerosing cholangitis through the SPRING trial, related open-label extension data, biomarker findings, macrophage-mediated mechanism research, and peer-reviewed or medical-meeting presentations.
Company news also covers financial results, corporate updates, regulatory interactions with agencies, preparations for later-stage development, strategic partnering discussions, capital-raising activity involving American Depositary Shares, and participation in healthcare and rare-disease investor conferences.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) will announce its third quarter 2022 financial results on November 11, 2022, at 8:00 am Eastern Time. The event will include a review of performance, recent developments, and a live Q&A session. The company is focused on developing therapeutics for fibrotic and inflammatory diseases, with its lead product, CM-101, in Phase 2 trials for conditions including liver fibrosis. A replay of the call will be available on the company’s website for 90 days following the event.
Chemomab Therapeutics Ltd (Nasdaq: CMMB), a clinical-stage biotechnology company, announced its participation in key scientific conferences in November 2022. Notably, it will present a poster on CCL24 Blockade at the AASLD - The Liver Meeting from November 4-8, and an oral presentation on CM-101 at the Union World Conference on Lung Health from November 8-11. These presentations aim to showcase advancements in therapeutics for fibrotic and inflammatory diseases.
Chemomab Therapeutics (CMMB) reported its Q2 2022 financial results, highlighting significant progress in its clinical programs, particularly CM-101, a monoclonal antibody targeting fibrosis and inflammation. The company concluded the treatment phase of a Phase 2 trial for liver fibrosis in NASH patients, with topline results expected by year-end. Chemomab also received a U.S. patent for CM-101 in liver diseases, extending its protection until at least 2038. Financially, the company had $51.8 million in cash, with a net loss of $6.2 million for the quarter.
Chemomab Therapeutics (Nasdaq: CMMB) announced the appointment of Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development. These appointments aim to strengthen the development of CM-101, a monoclonal antibody targeting fibrotic and inflammatory diseases. Key upcoming events include reporting topline results from a Phase 2 trial in liver fibrosis and launching a Phase 2 trial for systemic sclerosis. Both executives bring significant expertise that is expected to accelerate Chemomab's clinical activities and pipeline programs.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) announced it will release its second quarter 2022 financial results and provide a business update on August 12, 2022, at 8:00 am Eastern Time. During this event, the management team will review Q2 performance, discuss recent developments, and host a live Q&A session. The company specializes in developing therapeutics for fibrotic and inflammatory diseases, focusing on its monoclonal antibody CM-101, which is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) reported significant findings from presentations at the 2022 EASL International Liver Congress and the First International Extracellular Matrix Pharmacology Congress. The data highlights the role of the soluble protein CCL24 in liver diseases, specifically primary sclerosing cholangitis (PSC). Findings suggest that Chemomab's CCL24 neutralizing antibody CM-101 can effectively influence extracellular matrix remodeling, showing promise in clinical applications for PSC. The studies support the ongoing development of CM-101 in Phase 2 trials.
Chemomab Therapeutics (Nasdaq: CMMB) has appointed Jill M. Quigley to its board of directors. Quigley brings over 20 years of experience in biotechnology leadership, including executive roles in management, operations, and legal affairs. Her expertise includes working with companies focused on innovative therapeutics for rare diseases. Chemomab is advancing its antibody CM-101 through clinical trials for serious conditions like primary sclerosing cholangitis and systemic sclerosis. This appointment is expected to enhance Chemomab's strategic direction and operational efficacy.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) announced its participation in various investor and scientific conferences in June 2022, aimed at presenting its groundbreaking work in fibrotic and inflammatory diseases. Notable events include the JMP Securities Life Sciences Conference on June 16 in New York, and the Extracellular Matrix Pharmacology Congress from June 23-25 in Copenhagen. Chemomab's lead asset, CM-101, is in Phase 2 trials for several severe conditions, including primary sclerosing cholangitis, and is expected to advance into systemic sclerosis trials later this year.
Chemomab Therapeutics reported significant findings regarding CCL24 as a therapeutic target for systemic sclerosis at the EULAR European Congress of Rheumatology. Their CCL24-neutralizing antibody, CM-101, is set to enter Phase 2 trials later this year. The study indicated elevated CCL24 levels correlated with disease activity and prognosis in diffuse cutaneous systemic sclerosis patients. These findings strengthen the rationale for CM-101's clinical trials, aimed at addressing a critical unmet need in treating this severe autoimmune disease.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company, will participate in the virtual H.C. Wainwright Global Investment Conference from May 23-26, 2022. Management will deliver a corporate overview webcast available on demand starting at 7:00 am ET on May 24. Additionally, Chemomab will engage in one-on-one meetings with investors. The company focuses on innovative therapeutics for fibrotic and inflammatory diseases, with its CM-101 monoclonal antibody currently in Phase 2 trials for severe conditions like primary sclerosing cholangitis and lung fibrosis.